162 related articles for article (PubMed ID: 17519075)
21. A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.
Salinger DH; Endres CJ; Martin DA; Gibbs MA
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):276-83. PubMed ID: 27128833
[TBL] [Abstract][Full Text] [Related]
22. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Papp KA; Leonardi C; Menter A; Ortonne JP; Krueger JG; Kricorian G; Aras G; Li J; Russell CB; Thompson EH; Baumgartner S
N Engl J Med; 2012 Mar; 366(13):1181-9. PubMed ID: 22455412
[TBL] [Abstract][Full Text] [Related]
23. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Sofen H; Smith S; Matheson RT; Leonardi CL; Calderon C; Brodmerkel C; Li K; Campbell K; Marciniak SJ; Wasfi Y; Wang Y; Szapary P; Krueger JG
J Allergy Clin Immunol; 2014 Apr; 133(4):1032-40. PubMed ID: 24679469
[TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis.
Bissonnette R; Papp K; Maari C; Yao Y; Robbie G; White WI; Le C; White B
J Am Acad Dermatol; 2010 Mar; 62(3):427-36. PubMed ID: 20159310
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Leonardi CL; Kimball AB; Papp KA; Yeilding N; Guzzo C; Wang Y; Li S; Dooley LT; Gordon KB;
Lancet; 2008 May; 371(9625):1665-74. PubMed ID: 18486739
[TBL] [Abstract][Full Text] [Related]
28. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
Papp KA; Bressinck R; Fretzin S; Goffe B; Kempers S; Gordon KB; Caro I; Walicke PA; Wang X; Menter A;
Int J Dermatol; 2006 May; 45(5):605-14. PubMed ID: 16700803
[TBL] [Abstract][Full Text] [Related]
29. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.
Skov L; Kragballe K; Zachariae C; Obitz ER; Holm EA; Jemec GB; Sølvsten H; Ibsen HH; Knudsen L; Jensen P; Petersen JH; Menné T; Baadsgaard O
Arch Dermatol; 2003 Nov; 139(11):1433-9. PubMed ID: 14623703
[TBL] [Abstract][Full Text] [Related]
30. Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab.
Bissonnette R; Langley RG; Papp K; Matheson R; Toth D; Hultquist M; Geba GP; White B
Arch Dermatol Res; 2009 Jul; 301(6):429-42. PubMed ID: 19471949
[TBL] [Abstract][Full Text] [Related]
31. Treatment of psoriasis with interleukin-12/23 monoclonal antibody: a systematic review.
Wu Y; Chen J; Li YH; Ma GZ; Chen JZ; Gao XH; Chen HD
Eur J Dermatol; 2012; 22(1):72-82. PubMed ID: 22266126
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
Kimball AB; Gordon KB; Langley RG; Menter A; Chartash EK; Valdes J;
Arch Dermatol; 2008 Feb; 144(2):200-7. PubMed ID: 18283176
[TBL] [Abstract][Full Text] [Related]
33. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
Krueger GG; Langley RG; Leonardi C; Yeilding N; Guzzo C; Wang Y; Dooley LT; Lebwohl M;
N Engl J Med; 2007 Feb; 356(6):580-92. PubMed ID: 17287478
[TBL] [Abstract][Full Text] [Related]
34. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
Papp KA; Reich K; Paul C; Blauvelt A; Baran W; Bolduc C; Toth D; Langley RG; Cather J; Gottlieb AB; Thaçi D; Krueger JG; Russell CB; Milmont CE; Li J; Klekotka PA; Kricorian G; Nirula A
Br J Dermatol; 2016 Aug; 175(2):273-86. PubMed ID: 26914406
[TBL] [Abstract][Full Text] [Related]
35. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Reich K; Gooderham M; Thaçi D; Crowley JJ; Ryan C; Krueger JG; Tsai TF; Flack M; Gu Y; Williams DA; Thompson EHZ; Paul C
Lancet; 2019 Aug; 394(10198):576-586. PubMed ID: 31280967
[TBL] [Abstract][Full Text] [Related]
36. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
Paul C; Lacour JP; Tedremets L; Kreutzer K; Jazayeri S; Adams S; Guindon C; You R; Papavassilis C;
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910
[TBL] [Abstract][Full Text] [Related]
37. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects.
Khalilieh S; Hodsman P; Xu C; Tzontcheva A; Glasgow S; Montgomery D
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):294-300. PubMed ID: 29510001
[TBL] [Abstract][Full Text] [Related]
40. Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies.
Langley RG; Papp K; Bissonnette R; Toth D; Matheson R; Hultquist M; White B
Int J Dermatol; 2010 Jul; 49(7):818-28. PubMed ID: 20618506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
